Bibliography
- Blennow K , de Leon MJ, Zetterberg H: Alzheimer‘s disease. Lancet368, 387–403(2006).
- Blennow K , HampelH: Cerebrospinal fluid markers for incipient Alzheimer‘s disease.Lancet Neurol.2, 605–613(2003).
- Blennow K , WallinA, HägerO: Low frequency of post-lumbar puncture headache in demented patients.Acta Neurol. Scand.88, 221–223(1993).
- Peskind ER , RiekseR, QuinnJFet al.: Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord.19, 220–225(2005).
- Andreasen N , MinthonL, DavidssonPet al.: Evaluation of CSF-τ and CSF-Aβ42 as diagnostic markers for Alzheimer‘s disease in clinical practice. Arch. Neurol.58, 373–379(2001).
- Blennow K : CSF biomarkers for Alzheimer‘s disease: use in early diagnosis and evaluation of drug treatment.Expert Rev. Mol. Diagn.5, 661–672(2005).
- Buerger K , ZinkowskiR, TeipelSJet al.: Differential diagnsis of Alzheimer‘s disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol.59, 1267–1272(2002).
- Hampel H , BuergerK, ZinkowskiRet al.: Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a Comparative Cerebrospinal Fluid Study. Arch. Gen. Psychiatry61, 95–102(2004).
- Petersen RC , SmithGE, WaringSC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol.56, 303–308(1999).
- Hansson O , ZetterbergH, BuchhaveP, LondosE, BlennowK, MinthonL: Association between CSF biomarkers and incipient Alzheimer‘s disease in patients with mild cognitive impairment: a follow-up study.Lancet Neurol.5, 228–234(2006).
- Skoog I , DavidssonP, AevarssonO, VandersticheleH, VanmechelenE, Blennow K: Cerebrospinal fluid β-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement. Geriatr. Cogn. Disord.15, 169–176(2003).
- Gustafson DR , SkoogI, RosengrenL, ZetterbergH, BlennowK: Cerebrospinal fluid β-amyloid 1–-42 concentration may predict cognitive decline in older women.J. Neurol. Neurosurg. Psychiatr.78, 461–464(2007).
- Stomrud E , HanssonO, BlennowK, MinthonL, LondosE: Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy controls.Dement. Geriatr. Cogn. Disord.24, 118–124(2007).
- Fagan AM , RoeCM, XiongC, MintunMA, MorrisJC, HoltzmanDM: Cerebrospinal fluid τ/β-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.Arch. Neurol.64, 343–349(2007).
- Davidsson P , BlennowK, AndreasenN, ErikssonB, MinthonL, HesseC: Differential increase in cerebrospinal fluid-acetylcholine esterase after treatment with acetylcholine esterase inhibitors in patients with Alzheimer‘s disease.Neurosci. Lett.300, 157–160(2001).
- Parnetti L , AmiciS, LanariAet al.: Cerebrospinal fluid levels of biomarkers and activity of acetyl cholinesterase and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol. Sci.23, S95–S96 (2002).
- Blennow K , ZetterbergH, MinthonLet al.: Longitudinal stability of CSF biomarkers in Alzheimer‘s disease. Neurosci. Lett.419, 18–22(2007).
- Zetterberg H , PedersenM, LindKet al.: Intra-individual stability of CSF biomarkers for Alzheimer‘s disease over two years. J. Alzheimers Dis.12, 255–260(2007).
- Gilman S , KollerM, BlackRSet al.; AN1792(QS-21)-201 Study Team: Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology64, 1553–1562(2005).
- Siemers ER , QuinnJF, KayeJet al.: Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer‘s disease. Neurology66, 602–604(2006).
- Lanz TA , HimesCS, PallanteGet al.: The γ-secretase inhibitor N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther.305, 864–871(2003).